CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix. In development of this treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn's inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.


While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. The first CytoDyn post of mine, "CytoDyn: What In order to Do When It is Too Good to be able to Be True?", set out the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire job interview that I came away with a poor impression of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, yet the disappointment hasn't been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today's payment of $3.5 million transfers ownership of the expertise and associated intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) as well as the first new drug application endorsement ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn's helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it's this single treatments in addition to a "broad pipeline of indications" since it places it. I call such pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic company with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple presentations.

Might all of it be smoke cigarettes and mirrors? That's a question I've been asking myself through the really start of my interest in this particular business. Judging by way of the multiples of a huge number of various comments on listings accessible through Seeking Alpha's CytoDyn Summary webpage, I'm far from alone in this question.

CytoDyn is a classic battleground, or perhaps some might say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *